Ask AI
Modifying Obesity Treatment

CE / CME

Primary Care Strategies for Modifying Obesity Treatment Based on Weight Loss Goals, Comorbidities, and Adverse Event Management

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: February 21, 2025

Expiration: February 20, 2026

Activity

Progress
1
Course Completed

  1. Abdelaal M, le Roux CW, Docherty NG. Morbidity and mortality associated with obesity. Ann Transl Med. 2017;5:161.
  2. Malhotra A, Bednarik J, Sujatro Chakladar, et al. Tirzepatide for the treatment of obstructive sleep apnea: rationale, design, and sample baseline characteristics of the SURMOUNT-OSA phase 3 trial. Contemp Clin Trials. 2024;141:107516.
  3. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221-2232.
  4. Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21:169.
  5. Chuang MH, Chen JY, Wang HY, et al. Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes. JAMA Network Open. 2024;7:e2427258.
  6. Slowik JM, Collen JF. Obstructive sleep apnea. ncbi.nlm.nih.gov/books/NBK459252/. Accessed February 14, 2025.
  7. Jehan S, Zizi F, Pandi-Perumal SR, et al. Obstructive Sleep apnea and obesity: implications for public health. Sleep Med Disord. 2017;1:00019.
  8. El-Solh AA, Gould E, Aibangbee K, et al. Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review. Expert Opin Pharmacother. 2025;26:51-62.
  9. Tirzepatide [prescribing information]. Indianapolis, IN: Lilly; 2024.
  10. Freeman NLB, Browder SE, McGinigle KL. Balancing evidence-based care with patient-centered individualized care. J Vasc Surg Venous Lymphat Disord. 2023;11:1089-1094.
  11. Jastreboff AM, Aronne LJ, Stefanski A. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:1434-1435
  12. Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with glp-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12:145.
  13. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331:38-48.
  14. Phentermine/topiramate [prescribing information]. Campbell, CA: Vivus; 2022.
  15. Naltrexone/bupropion [prescribing information]. Brentwood, TN: Nalpropion; 2024.